Reading GRI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GRI free→Reading GRI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GRI free→QuarterlyIQ Insights · GRI
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
and Exhibit 99.1 is being furnished and, except as otherwise set forth in this Current Report on Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying Exhibit 99.1 shall not be deemed, except as otherwise set forth in this Current Report o…
Results of Operations and Financial Condition. On February 4, 2026, GRI Bio, Inc. (the “Company”) issued a press release reiterating its financial results for the fiscal year 2025 and summarizing key recent highlights. A copy of the Company’s press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Se…
Entry into a Material Definitive Agreement. As previously reported, on May 20, 2024, GRI Bio, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may from time to time issue and sell through Wainwright, acting as the Company’s sales agent, shares of the Company’s common stock, par value $0.0001 per share (the “Shares”) (the “ATM Offering”). In connection therewith, on May 20…
Material Modifications to Rights of Security Holders. To the extent required by Item 3.03, the disclosure set forth in
Other Events. On January 9, 2026, GRI Bio, Inc. (the “Company”) filed a prospectus supplement to increase the maximum number of shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share, issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC, dated May 20, 2024 (the “Sales Agreement”), to up to an aggregate of $7,379,813 of Shares, which does not include the Shares having an aggregate gross sales price of approximate…
Other Events. GRI Bio, Inc. (the “Company”) has received topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”). This topline data indicates that the trial met its primary endpoint and certain secondary endpoints that have been evaluated to date demonstrating that GRI-0621 was well tolerated over a 12-week treatment period, consistent with earlier studies evaluating over 1,700 subjects treated for up to a ye…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 26, 2025, the Company received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Quarterly Report on Form 10…
of this Current Report on Form 8-K is hereby incorporated by reference. Of the Company’s 2,496,800 shares of common stock issued and outstanding and eligible to vote as of the record date of July 8, 2025, a quorum of 1,090,373 shares, or approximately 43.67% of the eligible shares, was present in person or represented by proxy at the Annual Meeting. Each of the matters set forth below is described in detail in the Company’s Proxy Statement. The following actions were taken at the Annual Meeti…
Other Events. On May 23, 2025, GRI Bio, Inc. (the “Company”) filed a prospectus supplement to increase the maximum number of shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share, issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC, dated May 20, 2024 (the “Sales Agreement”), to up to an aggregate of $1,758,934 of Shares, which does not include the Shares having an aggregate gross sales price of approximately…
Results of Operations and Financial Condition. On May 15, 2025, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the three months ended March 31, 2025, and provided a business update. A copy of this press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Sec…
Other Events. On May 5, 2025, GRI Bio, Inc. (the “Company”) filed a prospectus supplement to increase the maximum number of shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share, issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC, dated May 20, 2024 (the “Sales Agreement”), to up to an aggregate of $1,670,956 of Shares, which does not include the Shares having an aggregate gross sales price of approximately $…
Changes in the Registrant's Certifying Accountant. (a) Dismissal of Previous Independent Registered Public Accounting Firm On April 11, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of GRI Bio, Inc. (the “Company”) approved the dismissal of Sadler Gibb & Associates LLC (“Sadler”) as the Company’s independent registered public accounting firm. The dismissal was not related to any disagreements with Sadler on any matter of accounting principles or practices, financ…
Other Events. Press Release On April 1, 2025, the Company issued a press release announcing the pricing of the Offering. A copy of such press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K and certain of the materials filed herewith contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securi…
Entry Into a Material Definitive Agreement. Securities Purchase Agreement On April 1, 2025, GRI Bio, Inc. (the “Company”) commenced a best efforts public offering (the “Offering”) of an aggregate of (i) 202,000 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of the Company, (ii) 1,186,888 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,186,888 shares of Common Stock (the “Pre-Funded Warrant Shares”), (iii) 1,388,888 Series E-1 warrants…
Results of Operations and Financial Condition. On March 17, 2025, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the year ended December 31, 2024, and provided a business update. A copy of this press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securi…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 10, 2025, GRI Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price deficiency under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"), which the Company previously reported on in its Current Reports on Form 8-K filed on September 10, 2024 and Form 8-K/A file…
Material Modifications to Rights of Security Holders. To the extent required by Item 3.03, the disclosure set forth in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.